title: Ventricular pacing threshold and time to capture postdefibrillation in patients undergoing implantable cardioverter-defibrillator implantation.
abstract: To assess the effect of defibrillation and amiodarone on ventricular pacing threshold and time to capture in patients undergoing automatic implantable cardioverter-defibrillator (AICD) implantation, 28 patients were prospectively evaluated. The patients were entered into one of two protocols: Ia--epicardial ventricular pacing threshold measured at baseline (preventricular fibrillation induction) and 10 and 60 seconds postdefibrillation with 20 J, or Ib--two fibrillation-defibrillation sequences were performed 3 minutes apart and ventricular pacing thresholds were measured for each sequence at baseline and at 10 and 60 seconds postdefibrillation with 20 J. Ten patients also underwent asynchronous pacing at 1.1 times baseline threshold during ventricular fibrillation with measurement of time to capture postdefibrillation. All patients were randomly assigned to receive either amiodarone or no antiarrhythmic drug therapy. Ventricular fibrillation was induced with AC (applied for 1-2 seconds), and standard epicardial bipolar and epicardial patch electrodes of the AICD were used for pacing and defibrillation, respectively. Ventricular pacing threshold at baseline, 10 seconds, 60 seconds, and 3 minutes postdefibrillation did not differ significantly. There were no significant differences in patients with or without amiodarone therapy. Furthermore, there was no transient loss of ventricular capture postdefibrillation or significant difference in time to capture with amiodarone (less than or equal to 2 seconds). We conclude that following internal defibrillation with 20 J: (1) ventricular pacing threshold at 10 seconds, 60 seconds, and 3 minutes were not significantly different from baseline with one or two fibrillation-defibrillation sequences, (2) time to capture was short, and (3) there was no significant difference in no drug versus amiodarone. These findings have direct clinical importance in considering device therapy with both pacing and defibrillating capabilities.
authors.affiliation: Department of Medicine, Sinai Hospital of Baltimore, Maryland 21215.
authors.forename: T
authors.initials: T
authors.lastname: Khastgir
authors.forename: J
authors.initials: J
authors.lastname: Lattuca
authors.forename: D
authors.initials: D
authors.lastname: Aarons
authors.forename: J
authors.initials: J
authors.lastname: Murphy
authors.forename: V
authors.initials: V
authors.lastname: O'Mara
authors.forename: J
authors.initials: J
authors.lastname: Juanteguy
authors.forename: E P
authors.initials: EP
authors.lastname: Veltri
mesh_terms: D000638:Amiodarone / Q000627:therapeutic use; D002304:Cardiac Pacing, Artificial / Q000379:methods*; D004554:Electric Countershock / Q000295:instrumentation; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010138:Pacemaker, Artificial; D011446:Prospective Studies; D013610:Tachycardia / Q000503:physiopathology / Q000628:therapy; D013997:Time Factors; D014693:Ventricular Fibrillation / Q000503:physiopathology / Q000628:therapy; D016276:Ventricular Function / Q000187:drug effects / Q000502:physiology*
chemical_list: D000638:Amiodarone